PLAU

PLAU Overview

English NameUrokinase plasminogen activatorApproved Drugs4
Drugs in Clinical Trials5Target SynonymPLAU,uPA,Plasminogen Activator, Urokinase,Urokinase-Type Plasminogen Activator,Plasminogen Activator, Urinary,BDPLT5,U-PA,ATF,QPD,URK,EC 3.4.21,EC:3.4.21.73,U-Plasminogen Activator,EC 3.4.21.73
Highest Development StageApproved
English NameUrokinase plasminogen activator
Target SynonymPLAU,uPA,Plasminogen Activator, Urokinase,Urokinase-Type Plasminogen Activator,Plasminogen Activator, Urinary,BDPLT5,U-PA,ATF,QPD,URK,EC 3.4.21,EC:3.4.21.73,U-Plasminogen Activator,EC 3.4.21.73
Approved Drugs4
Drugs in Clinical Trials5
Highest Development StageApproved

PLAU Product List

  • Product Category

    Protein (2)

  • Product Status

    Launched (2)

  • Species

    Human (2)

  • Tag

    His Tag (2)

  • Conjugate

    Unconjugated (2)

Cat. No.SpeciesHostProduct DescriptionStructurePurityFeature
PLU-H5228
Human
HEK293
Human PLAU / uPA Protein, His Tag (activated by trypsin) (active enzyme)
PLU-H5229
Human
HEK293
Human PLAU / uPA Protein, His Tag
Total: 2
  • 1

PLAU Background

Urokinase - type plasminogen activator is also known as PLAU and UPA, a serine protease with an extremely limited substrate specificity, cleaving the sequence Cys – Pro – Gly - Arg560 - Val561 – Val – Gly – Gly – Cys in plasminogen to form plasmin. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium.uPA and its receptor (uPAR) have been implicated in a broad spectrum of pathophysiological processes, including fibrinolysis, proteolysis, inflammation, atherogenesis and plaque destabilization, all of which are involved in the pathogenesis of MI (myocardial infarction).

PLAU Synonyms

Urokinase,PLAU,ATF,UPA,URK,u-PA,BDPLT5,QPD

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
tPA/HisproUK (Thrombolytic Science)TS-01Phase 2 ClinicalThrombolytic ScienceIschemic Stroke
Details
Upamostat Hydrogen SulphateWX-671; LH-011; RHB-107Phase 2 ClinicalWilex AGCoronavirus Disease 2019 (COVID-19); Metastatic breast cancer; Pancreatic Neoplasms
Details
MicrolyseTGD-001Phase 2 ClinicalUniversity Medical Centre Utrecht, NetherlandsIschemic Stroke; Purpura, Thrombotic Thrombocytopenic; Thrombocytopenia; Thrombotic Microangiopathies
Details
Recombinant annexin A5 (Annexin Pharmaceuticals)ANXV; ANXV (Annexin A5); ANXV (Human Recombinant Annexin A5)Phase 2 ClinicalAnnexin Pharmaceuticals ABAnemia, Sickle Cell; Cardiovascular Diseases; Diabetic Retinopathy; Neoplasms; Retinal Vein Occlusion
Details
MSB-03MSB-03Phase 1 ClinicalMatriSys Bioscience IncRosacea
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
Urokinase biosimilar (Sedico)ApprovedSedicoAngikinaseEgyptThromboembolism; Myocardial Infarction; Pulmonary EmbolismSedico2014-01-01Myocardial Infarction; Pulmonary Embolism; Thromboembolism
Details
TisokinaseAK-124ApprovedAsahi Kasei Corp, Kowa Dental Health Co LtdPlasvata, HapaseJapanMyocardial Infarction; Thrombosisnull1991-01-01Myocardial Infarction; Thrombosis
Details
Urokinase biosimilar (Bharat Serums & Vaccines)U-FRAGApprovedBharat Serums And Vaccines LtdPulmonary Embolism
Details
NasaruplaseGE-0943ApprovedMitsubishi Pharma CorpTomieze, ThrombolyseJapanMyocardial Infarction; Venous ThrombosisMitsubishi Pharma Corp1992-01-01Myocardial Infarction; Venous Thrombosis
Details
  • Overview
  • Product List
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland